Business
US Patent Granted for SDC-1802 TYK2/JAK1 Inhibitor
US Patent Granted for SDC-1802 TYK2/JAK1 Inhibitor.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 3573O\n Sareum Holdings PLC\n 07 October 2021\n \n \n \n \n SAREUM HOLDINGS PLC\n \n \n (\"Sareum\" or \"the Company\")\n \n \n US Patent Granted for Sareum's SDC-1802 TYK2/JAK1 Inhibitor\n \n \n Cambridge, UK, 7 October 2021\n - \n Sareum Holdings plc (AIM: SAR), \n the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, announces\n \n that, further to its announcement of 30 July 2021, the United States Patent and Trademark Office has now formally approved its patent i\n n respect of an invention associated \n with Sareum's proprietary SDC-1802 TYK2/JAK1 Kinase Inhibitor Programme (the \"SDC-1802 Programme\"). \n \n \n The patent (US 11,154,539) will grant on 26 October 2021 and will protect the SDC-1802 molecule and pharmaceutical preparations thereof as a therapeutic to treat cancer selected from pancreatic, colorectal and kidney cancers, melanoma, and B-cell lymphoma by inhibiting TYK2 kinase. This programme is in preclinical development. \n \n \n Sareum's CSO, Dr John Reader, commented\n : \n \n \n \"We are pleased to confirm the grant of this US patent for SDC-1802, adding another layer of protection around this promising candidate in key territories. Our SDC-1802 programme is in preclinical development currently and we are designing the translational studies needed to define the optimal cancer application prior to completing toxicology and manufacturing studies. We look forward to providing further updates on progress as we achieve key milestones.\" \n \n \n For further information, please contact: \n \n \n \n \n \n Sareum Holdings plc\n \n \n Tim Mitchell, CEO\n \n \n \n \n \n \n \n \n \n \n 01223 497 700\n \n \n \n \n \n \n Strand Hanson Limited (Nominated Adviser)\n \n \n James Dance / James Bellman\n \n \n \n \n \n \n \n \n \n \n 020 7409 3494\n \n \n \n \n \n \n Hybridan LLP (Nominated Broker)\n \n \n Claire Noyce \n \n \n \n \n \n \n \n \n \n \n 020 3764 2341\n \n \n \n \n \n \n MEDiSTRAVA Consulting (Financial PR)\n \n \n Mark Swallow / David Dible\n \n \n \n \n \n \n \n 020 7638 9571\n \n \n \n \n \n About Sareum\n \n \n Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment o...